Aug 4, 2026 04:01PM
Jul 2, 2026 09:30PM
May 14, 2026 08:30AM
May 13, 2026 07:11AM
May 6, 2026 08:00AM
Apr 10, 2026 08:01AM
Apr 10, 2026 08:00AM Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Apr 7, 2026 08:30AM
Apr 2, 2026 08:00AM
Mar 31, 2026 08:00AM
Mar 16, 2026 08:13AM
Mar 12, 2026 08:00AM
Feb 26, 2026 08:00AM
Feb 10, 2026 08:03AM Milestone Pharmaceuticals names David Sandoval general counsel
Feb 10, 2026 08:00AM
Feb 3, 2026 08:00AM
Jan 26, 2026 08:02AM
Jan 26, 2026 08:00AM
Jan 13, 2026 06:09AM
Jan 6, 2026 08:02AM
Jan 6, 2026 08:00AM Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Dec 21, 2025 04:00AM
Dec 17, 2025 05:00PM
Dec 17, 2025 05:00PM
Dec 15, 2025 10:03AM
Dec 12, 2025 08:00PM
Dec 12, 2025 08:00PM
Nov 12, 2025 07:01AM Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Nov 4, 2025 04:05PM
Nov 3, 2025 08:00AM
Oct 9, 2025 08:00AM
Aug 19, 2025 08:00AM
Aug 12, 2025 07:05AM
Jul 11, 2025 09:32AM
Jul 11, 2025 09:30AM Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Jul 11, 2025 06:02AM
Jul 11, 2025 06:01AM
Jul 11, 2025 06:00AM
Jul 11, 2025 06:00AM
Jun 17, 2025 06:39AM
Jun 16, 2025 08:03AM
Jun 16, 2025 08:00AM Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
May 14, 2025 07:04AM
Apr 10, 2025 08:30AM
Apr 1, 2025 06:13AM
Mar 28, 2025 07:00AM
Mar 28, 2025 07:00AM
Mar 20, 2025 08:00AM
Mar 18, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
Mar 13, 2025 07:08AM

327,437 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All